TRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium Therapeutics Inc. - TRIL
NEW ORLEANS--(BUSINESS WIRE)--Aug 23, 2021--
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Trillium Therapeutics Inc. (NasdaqCM: TRIL) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Trillium will receive only $18.50 in cash for each share of Trillium that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( email@example.com ) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-tril/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210823005678/en/
CONTACT: Kahn Swick & Foti, LLC
Lewis S. Kahn
KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA
INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES
SOURCE: Kahn Swick & Foti, LLC
Copyright Business Wire 2021.
PUB: 08/23/2021 08:05 PM/DISC: 08/23/2021 08:06 PM